New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
11:58 EDTHLF, RPRX, NKTR, SPPI, CTXSStocks with increasing implied volatility; HLF RPRX NKTR SPPI CTXS
News For HLF;RPRX;NKTR;SPPI;CTXS From The Last 14 Days
Check below for free stories on HLF;RPRX;NKTR;SPPI;CTXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
07:16 EDTRPRXRepros Therapeutics price target raised to $30 on '305 results at BofA/Merrill
Subscribe for More Information
August 28, 2014
16:21 EDTRPRXOn The Fly: Closing Wrap
Subscribe for More Information
12:47 EDTHLFHerbalife volatility flat as shares at low end of 13-month range
Subscribe for More Information
12:34 EDTRPRXOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as concern over the Ukraine crisis overshadowed an upward revision to the government's estimate of U.S. economic growth in the second quarter. The major averages began the session in negative territory and picked up downside momentum in early trading, but soon after began to drift off their lows and recapture some of their losses. Volume remains light, as is expected ahead of the upcoming long weekend. ECONOMIC EVENTS: In the U.S., Q2 GDP growth was unexpectedly boosted to 4.2% from the first estimate of 4.0%. Personal consumption rose 2.5% during the second quarter, versus estimates for a 2.4% increase. Initial jobless claims ticked down slightly to 298K in the fourth week of August. Pending home sales index increased 3.3% in July, which was better than the 0.5% month-over-month increase that was expected. In Europe, Ukraine president Poroshenko reportedly accused Russia of a "de facto" invasion and canceled a trip to call an urgent meeting of his security and defense council. COMPANY NEWS: Shares of Visa (V) declined 1% after Raymond James lowered its rating on the credit card giant's stock to Market Perform from Outperform. The Dow component faces a number of headwinds, including tougher negotiating tactics by larger international banks looking to win better deals, lower cross-border volume, and loss of processing revenue in Russia, wrote Raymond James analyst Wayne Johnson. MAJOR MOVERS: Among the notable gainers was Repros Therapeutics (RPRX), which jumped 20% after the first of two identical pivotal studies comparing Androxal to an FDA approved topical gel and placebo achieved superiority in both co-primary endpoints and Piper Jaffray hiked its price target on the stock to $33 from $26. Also higher was Signet Jewelers (SIG), which rose nearly 7% after reporting Q2 results that analysts at Sterne Agee called "impressive." Among the noteworthy losers were a number of retailers who dropped after reporting results from their most recent fiscal quarters. Shares of home goods retailer William-Sonoma (WSM) dropped 11%, jeans maker Guess (GES) fell 9%, and apparel retailer Abercrombie & Fitch (ANF) slipped more than 4%. INDEXES: Near midday, the Dow was down 33.92, or 0.2%, to 17,088.09, the Nasdaq was down 4.52, or 0.1%, to 4,565.11, and the S&P 500 was down 2.04, or 0.1%, to 1,998.08.
11:57 EDTRPRXRepros next Androxal trial should hit endpoints also, says Brean Capital
Subscribe for More Information
10:25 EDTRPRXHigh option volume stocks
Subscribe for More Information
10:10 EDTRPRXRepros Therapeutics price target raised to $33 from $26 at Piper Jaffray
Subscribe for More Information
08:55 EDTRPRXOn The Fly: Pre-market Movers
HIGHER: Digital Ally (DGLY), up 16% after announcing order from Michigan State Police for over $1.1M... EnteroMedics (ETRM), up 12.4% after reporting three-year data from Maestro RC system... Repros (RPRX), up 0.8% after Androxal achieves superiority in both co-primary endpoints in a study... Synthetic Biologics (SYN), up 2.7% after Pfizer (PFE) was granted FDA Fast Track designation for its investigational Clostridium difficile vaccine candidate. Synthetic Biologics announced earlier this week that SYN-004, the company's lead anti-infective product candidate for the prevention of the effects of C. difficile, will be presented in October... Signet (SIG), up 3.9% after Q2 revenue tops consensus. DOWN AFTER EARNINGS: Abercrombie & Fitch (ANF), down 5.7%... Guess (GES), down 8.3%... Frontline (FRO), down 7%. ALSO LOWER: Williams-Sonoma (WSM), down 10.9% after downgraded at Morgan Stanley following the company's Q2 earnings report... GT Advanced (GTAT), down 2% after downgraded at Raymond James... Sungy Mobile (GOMO), down 20.1% following earnings report, CFO resignation, downgrade of stock at Oppenheimer... Genesco (GCO), down 7.7% after cutting fiscal year forecast.
07:29 EDTRPRXRepros Therapeutics to host conference call
Conference call to discuss Androxal's top line results will be held on August 28 at 9 am. Webcast Link
05:10 EDTRPRXRepros reports Androxal achieves superiority in both co-primary endpoints
Subscribe for More Information
August 27, 2014
11:09 EDTHLFHerbalife at highs following Icahn tweet
Subscribe for More Information
09:08 EDTNKTRNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
August 26, 2014
11:12 EDTRPRXHigh option volume stocks
Subscribe for More Information
August 25, 2014
11:44 EDTHLFStocks with call strike movement; PVA HLF
Subscribe for More Information
August 22, 2014
14:28 EDTHLFHerbalife off earlier lows, levels to watch
Subscribe for More Information
13:45 EDTHLFAckman likely pressed bearish options bet on Herbalife, CNBC reports
Bill Ackman of Pershing Square likely pressed his bearish options bet on Herbalife, based on options trading activity, CNBC's Scott Wapner reports.
11:05 EDTRPRXPiper Jaffray biopharm analyst holds an analyst/industry conference call
Subscribe for More Information
09:01 EDTRPRXRepros Therapeutics has favorable near-term catalysts, says BofA/Merrill
BofA/Merrill lowered Repros Therapeutics' price target to $27 from $32 due to competitive pricing and a contraction in the TRT market but says it expects favorable near-term data from Androxal and AndroGel studies. The firm expects the Sept 17 FDA meeting to access DV risks from exogenous testosterone to be favorable. Shares are Buy rated.
August 21, 2014
15:37 EDTNKTRNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
10:02 EDTSPPISpectrum weakness attributed to FDA comment on Fusilev generics
The move lower in shares of Spectrum is being attributed to circulation of a Department of Health and Human Services document which states the FDA will be able to approve abbreviated new drug applications for levoleucovorin calcium, the trade name of Spectrum's Fusilev. Shares of Spectrum are down 4%, or 33c, to $7.42. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use